Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow BOLT
Bolt Biotherapeutics, Inc. (BOLT) EV/Sales
As of 16 October 2026, Bolt Biotherapeutics, Inc. (BOLT) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from −54.8× (May 2022) to 314× (October 2021); the current reading is higher than 96% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.3× | — |
| FY2024 | −0.6× | — |
| FY2023 | −5.2× | — |
| FY2022 | −17.0× | — |
| FY2021 | −1.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 228.77% |
| Mar 2026 | 0.5× | 35.87% |
| Dec 2025 | 0.3× | — |
| Sep 2025 | −0.3× | — |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IMRN IMMURON compare | −3.5× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| CSCIF COSCIENS Biopharma Inc. compare | 0.2× |
| SNTI Senti Biosciences, Inc. compare | 0.3× |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.3× |
| KPTI Karyopharm Therapeutics Inc. compare | 1.3× |
| BOLT Bolt Biotherapeutics, Inc. | 1.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)